Suchergebnisse - "Tankova, Tsvetalina"

PubPharm (10)

1

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

enthalten in: Diabetes care | 2022

von Davies, M. | Aroda, V. | Collins, B. | +11

2

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide : Insights From the EXSCEL Trial

enthalten in: Diabetes care | 2020

von Bethel, M. | Mentz, R. | Merrill, P. | +14

3

PIONEER 1 : Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

enthalten in: Diabetes care | 2019

von Aroda, V. | Rosenstock, J. | Terauchi, Y. | +102

4

Pancreatic Safety of Sitagliptin in the TECOS Study

enthalten in: Diabetes care | 2017

von Buse, J. | Bethel, M. | Green, J. | +13

CommentIn: Diabetes Care. 2017 Feb;40(2):161-163. - PMID 28108536

5

Pancreatic Safety of Sitagliptin in the TECOS Study

enthalten in: Diabetes care | 2017

von Buse, J. | Bethel, M. | Green, J. | +12

6

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes : Outcomes From TECOS

enthalten in: Diabetes care | 2016

von Cornel, J. | Bakris, G. | Stevens, S. | +14

7

Pancreatic Safety of Sitagliptin in the TECOS Study

enthalten in: Diabetes care | 2016

von Buse, J. | Bethel, M. | Green, J. | +12

8

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS

enthalten in: Diabetes care | 2016

von Cornel, J. | Bakris, G. | Stevens, S. | +13

9

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

enthalten in: Diabetes care | 2012

von Rosenstock, J. | Aggarwal, N. | Polidori, D. | +106

10

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes : the LEAD (liraglutide effect and action in diabetes)-2 study

enthalten in: Diabetes care | 2009

von Nauck, M. | Frid, A. | Hermansen, K. | +7

1
[1]